Company intelligence / Profile preview

Hepacon

New Jersey, United Stateshepacon.fi ↗

Ownership: Private
Employees: ~22
Development stage: Other

Overview

Rencofilstat showed promise in reducing liver fibrosis and tumor burden in preclinical models; clinical development reached Phase 2 for NASH/MASH but was halted due to lack of funds. Company has ceased further clinical work as an independent entity following merger announcement with Pharma Two B.

Therapeutic areas: GastroenterologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hepacon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepacon.

Explore the full profile